Abstract | BACKGROUND: METHODS: A clinical practice was instituted at Northwestern Memorial Hospital in Chicago in 2005, to administer amphotericin B deoxycholate nasal spray (ABNS) 0.5% to all HSCT recipients with fungal colonization of their nasal passages, in addition to standard oral antifungal prophylaxis. RESULTS: Among 1945 HSCT patients treated during the study period, 109 patients were identified with positive fungal surveillance cultures. CONCLUSION:
|
Authors | S M Trifilio, R Heraty, A Zomas, Z Zhou, J L Fong, D Liu, C Zhao, J Zhang, J Mehta |
Journal | Transplant infectious disease : an official journal of the Transplantation Society
(Transpl Infect Dis)
Vol. 17
Issue 1
Pg. 1-6
(Feb 2015)
ISSN: 1399-3062 [Electronic] Denmark |
PMID | 25620386
(Publication Type: Journal Article)
|
Copyright | © 2015 John Wiley & Sons A/S. Published by John Wiley & Sons Ltd. |
Chemical References |
- Antifungal Agents
- Drug Combinations
- Nasal Sprays
- Deoxycholic Acid
- Amphotericin B
- amphotericin B, deoxycholate drug combination
|
Topics |
- Adult
- Aged
- Aged, 80 and over
- Amphotericin B
(administration & dosage)
- Antifungal Agents
(administration & dosage)
- Deoxycholic Acid
(administration & dosage)
- Drug Combinations
- Female
- Hematopoietic Stem Cell Transplantation
(adverse effects)
- Humans
- Immunocompromised Host
- Male
- Middle Aged
- Mycoses
(prevention & control)
- Nasal Sprays
- Young Adult
|